ArticleEpilepsia open2026
Incidence and outcomes of childhood status epilepticus in Kano, northern Nigeria.
Article in Epilepsia open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Treatment outcome and its predictors among patients with status epilepticus in Africa: A systematic review and meta-analysis.Exploratory research in clinical and social pharmacy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
objectiveConvulsive status epilepticus (CSE) is a major neurological emergency in childhood, but population-based data from low- and middle-income countries remain limited. We estimated the incidence, mortality, neurological outcomes, and predictors of adverse outcomes among children with CSE in Kano, northern Nigeria.
methodsWe conducted a review of one-year surveillance data on childhood CSE across eight hospitals and a random sample of eight primary health centers in the Kano metropolis. Cases were identified using standardized definitions and weighted to account for sampling at primary health centers. Demographic and clinical data were collected at presentation and during hospitalization. Logistic regression analysis was used to identify predictors of mortality and new-onset neurological deficits.
resultsA total of 972 children with CSE were identified at participating hospitals, with additional cases detected at primary health centers. After weighting, an estimated 1921 CSE cases occurred during the study period, corresponding to an annual incidence of 98 per 100 000 children aged 1 month-14 years. Incidence was highest among infants (175 per 100 000). Among hospitalized children, in-hospital mortality was 24.7%, with more than half of the deaths occurring within 24 h of admission. New-onset neurologic deficits were observed in 9.6% of hospitalized survivors. In multivariable analysis, hypoglycemia at presentation, presumed meningoencephalitis, and CSE lasting longer than 30 min were independently associated with increased odds of death. Neurological deficits were associated with multiple CSE episodes, prolonged seizures, and presumed meningoencephalitis. SIGNIFICANCE: Childhood CSE in Kano is associated with a high incidence and substantial mortality, particularly among infants. Hypoglycemia, central nervous system infections, and prolonged seizures are key predictors of adverse outcomes. These findings highlight the need for improved early recognition and strengthened emergency seizure management in resource-limited settings. PLAIN LANGUAGE SUMMARY: Convulsive status epilepticus is a dangerous type of prolonged seizure in children. In this study from Kano, Nigeria, many children developed this condition and about one in four hospitalized patients died. Low blood sugar, suspected brain infections, and long seizures increased the risk of poor outcomes. Improving early treatment and emergency care may help reduce these deaths.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.